ClinicalTrials.Veeva

Menu

Study Of The Effects Of Atorvastatin On Cholesterol Levels In Rheumatoid Arthritis Patients Taking CP-690,550

Pfizer logo

Pfizer

Status and phase

Completed
Phase 2

Conditions

Rheumatoid Arthritis

Treatments

Drug: Atorvastatin Placebo
Drug: Atorvastatin
Drug: CP-690,550

Study type

Interventional

Funder types

Industry

Identifiers

NCT01059864
A3921109

Details and patient eligibility

About

All patients will be in instructed to eat a therapeutic lifestyle diet and will receive CP-690,550 throughout the 12 weeks of this study. After 6 weeks, half will receive the cholesterol lowering agent, atorvastatin, and half a matching placebo. This study will first measure the effects of CP-690,550 on cholesterol levels and then the effects of adding atorvastatin on those levels.

Enrollment

111 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • must be diagnosed as having active rheumatoid arthritis
  • agree to participate in the study and sign and informed consent document

Exclusion criteria

  • History of serious infection within the past 6 months
  • test positive for TB
  • have any uncontrolled clinically significant disease or laboratory tests
  • require administration of prohibited medications during the study

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

111 participants in 2 patient groups

Arm 1
Experimental group
Treatment:
Drug: Atorvastatin
Drug: CP-690,550
Drug: CP-690,550
Arm 2
Experimental group
Treatment:
Drug: CP-690,550
Drug: CP-690,550
Drug: Atorvastatin Placebo

Trial contacts and locations

15

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems